# Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence

> **NCT03197155** · — · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 68 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatitis C
- Direct Acting Antivirals

## Interventions

- **DRUG:** Direct Acting Antivirals against hepatitis C virus infection

## Key facts

- **NCT ID:** NCT03197155
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-01
- **Primary completion:** 2017-01-31
- **Final completion:** 2017-03-31
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2017-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03197155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03197155, "Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03197155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*